Tabula Rasa HealthCare Inc (TRHC) Given Average Recommendation of “Buy” by Brokerages

Shares of Tabula Rasa HealthCare Inc (NASDAQ:TRHC) have earned a consensus recommendation of “Buy” from the fourteen research firms that are presently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, four have given a hold recommendation, eight have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is $82.30.

TRHC has been the subject of several research analyst reports. Cantor Fitzgerald reissued a “buy” rating and set a $99.00 price objective on shares of Tabula Rasa HealthCare in a research note on Thursday, February 28th. Zacks Investment Research lowered Tabula Rasa HealthCare from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, January 22nd. BidaskClub raised Tabula Rasa HealthCare from a “sell” rating to a “hold” rating in a research note on Friday, March 22nd. ValuEngine lowered Tabula Rasa HealthCare from a “buy” rating to a “hold” rating in a research note on Monday, May 13th. Finally, Guggenheim initiated coverage on Tabula Rasa HealthCare in a research note on Wednesday, April 17th. They set a “neutral” rating and a $58.00 price target for the company.

In other news, CEO Calvin H. Knowlton sold 8,000 shares of the business’s stock in a transaction dated Monday, April 8th. The stock was sold at an average price of $54.50, for a total value of $436,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Calvin H. Knowlton sold 8,270 shares of the business’s stock in a transaction dated Tuesday, May 7th. The shares were sold at an average price of $53.68, for a total value of $443,933.60. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 48,270 shares of company stock valued at $2,565,774. Corporate insiders own 14.00% of the company’s stock.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. BlackRock Inc. lifted its stake in shares of Tabula Rasa HealthCare by 1.6% in the 4th quarter. BlackRock Inc. now owns 2,600,884 shares of the company’s stock valued at $165,831,000 after acquiring an additional 40,174 shares during the last quarter. M&T Bank Corp bought a new stake in shares of Tabula Rasa HealthCare in the 4th quarter valued at about $33,749,000. Peregrine Capital Management LLC lifted its stake in shares of Tabula Rasa HealthCare by 8.1% in the 4th quarter. Peregrine Capital Management LLC now owns 263,096 shares of the company’s stock valued at $16,775,000 after acquiring an additional 19,705 shares during the last quarter. Fiera Capital Corp bought a new stake in shares of Tabula Rasa HealthCare in the 4th quarter valued at about $2,268,000. Finally, Polar Capital LLP bought a new stake in shares of Tabula Rasa HealthCare in the 4th quarter valued at about $3,953,000. 76.85% of the stock is owned by institutional investors.

NASDAQ:TRHC traded up $1.19 during trading hours on Thursday, hitting $47.18. 4,961 shares of the company’s stock traded hands, compared to its average volume of 387,589. The firm has a market capitalization of $1.01 billion, a price-to-earnings ratio of 138.62 and a beta of 1.51. Tabula Rasa HealthCare has a 52 week low of $42.29 and a 52 week high of $91.16. The company has a debt-to-equity ratio of 1.31, a quick ratio of 1.73 and a current ratio of 1.80.

Tabula Rasa HealthCare (NASDAQ:TRHC) last posted its quarterly earnings data on Wednesday, May 8th. The company reported ($0.14) earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.14). The company had revenue of $60.96 million during the quarter, compared to analyst estimates of $59.24 million. Tabula Rasa HealthCare had a positive return on equity of 4.22% and a negative net margin of 18.15%. Equities analysts forecast that Tabula Rasa HealthCare will post -0.55 earnings per share for the current fiscal year.

About Tabula Rasa HealthCare

Tabula Rasa HealthCare, Inc operates as a healthcare technology company in the field of medication safety in the United States. The company's proprietary Medication Risk Mitigation Matrix delivers a multi-drug review, which identifies medication-related risks. Its cloud-based software applications include EireneRx, a medication decision-support and e-prescribing platform to access patients' medication-related information; and MedWise that provides medication decision support components for clients seeking to manage their medication risk and improve medication outcomes, and patient relationships by enhancing their existing systems.

Featured Story: Trading Options- What is a Strangle?

Analyst Recommendations for Tabula Rasa HealthCare (NASDAQ:TRHC)

Receive News & Ratings for Tabula Rasa HealthCare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tabula Rasa HealthCare and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit